Methotrexate subcutaneous auto-injection - Medac Pharma

Drug Profile

Methotrexate subcutaneous auto-injection - Medac Pharma

Alternative Names: Methotrexate ready-to-use autopen; Metoject® prefilled pen; Metojet® PEN; MPI-2505; Rasuvo; Subcutaneous injectable MTX - Medac Pharma

Latest Information Update: 05 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medac; Medac Pharma
  • Developer Medac Pharma
  • Class Abortifacients; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Benzamides; Disease-modifying antirheumatics; Glutamates; Pterins; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Juvenile rheumatoid arthritis; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 06 Oct 2014 Launched for Rheumatoid arthritis, Psoriasis and Juvenile rheumatoid arthritis in USA (SC) - first global launch
  • 01 Aug 2014 medac GmbH completes a clinical trial in Juvenile rheumatoid arthritis in USA (NCT02052167)
  • 10 Jul 2014 Registered for Juvenile rheumatoid arthritis (poly-articular-course) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top